Dave Ricks, Eli Lilly CEO (File photo/AP)
July 29, 2021 07:23 AM EDTUpdated 07:34 AM
Deals

Eli Lil­ly teams up with KRAS drug pi­o­neer Yi Liu tar­get­ing small mol­e­cule I/O with $70M up­front

Kyle Blankenship

Among the ma­jor drug­mak­ers, on­col­o­gy has be­come a gold rush in re­cent years with the big dogs hoover­ing up re­search part­ners along the way. One …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times